|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
4,540,000 |
Market
Cap: |
14.66(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.15 - $6.931 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aileron Therapeutics is a clinical stage chemoprotection oncology company. ALRN-6924, Co.'s MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. Co.'s clinical development program for ALRN-6924 as a selective chemoprotective agent includes: Its completed Phase 1b open-label clinical trial evaluating ALRN-6924 as a chemoprotective agent in patients with p53-mutated small cell lung cancer, undergoing treatment with second-line topotecan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
225 |
5,301 |
5,301 |
Total Buy Value |
$0 |
$758 |
$10,745 |
$10,745 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
2 |
2 |
Total Shares Sold |
63,781 |
63,781 |
63,781 |
63,781 |
Total Sell Value |
$265,104 |
$265,104 |
$265,104 |
$265,104 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
7 |
7 |
7 |
7 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kck Ltd. |
10% Owner |
|
2017-07-05 |
4 |
B |
$15.00 |
$3,000,000 |
D/D |
200,000 |
646,817 |
2.45 |
- |
|
Kck Ltd. |
10% Owner |
|
2017-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
446,817 |
446,817 |
|
- |
|
Roche Finance Ltd |
10% Owner |
|
2017-07-05 |
4 |
B |
$15.00 |
$1,791,000 |
D/D |
119,400 |
702,363 |
2.45 |
- |
|
Roche Finance Ltd |
10% Owner |
|
2017-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
579,093 |
582,963 |
|
- |
|
Kapnick Scott |
Director |
|
2017-06-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,638 |
|
- |
|
Apple Tree Partners Ii Lp |
10% Owner |
|
2017-06-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
251 |
|
- |
|
Yanchik Joseph A. Iii |
See RemarksOfficer |
|
2017-06-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
123,796 |
|
- |
|
Platt Jon B. |
10% Owner |
|
2017-06-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100 |
|
- |
|
108 Records found
|
|
Page 5 of 5 |
|
|